Coherus BioSciences Reports the Launch of Loqtorzi (toripalimab-tpzi) across the United States to Treat Nasopharyngeal Carcinoma (NPC)
Shots:
- Loqtorzi is indicated in combination with cisplatin & gemcitabine for the 1L treatment of adults with metastatic or recurrent locally advanced NPC & as a monotx. for adults with recurrent/unresectable/metastatic NPC
- In Dec 2023, the NCCN committee preferred Loqtorzi as a category 1 treatment option in combination with cisplatin & gemcitabine based on the results from the P-III (JUPITER-02) & P-II (POLARIS-02) trials
- In the P-III (JUPITER-02) trial, Loqtorzi +CT significantly improved PFS & reduced the risk of disease progression or death by 48% along with an improved OS. In the P-II (POLARIS-02) study Loqtorzi showed durable anti-tumor activity in recurrent/metastatic NPC patients with an ORR of 20.5%, DCR of 40% & mOS of 17.4mos.
Ref: Coherus | Image: Coherus
Related News:- Coherus and Junshi Biosciences Received the US FDA’s Approval for Loqtorzi (toripalimab-tpzi) to Treat Nasopharyngeal Carcinoma (NPC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
